In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression

British Journal of Haematology

Volumn 113, Issue 3, 2001, Pages 794-802

  Rawstron, A C ^a   Barrans, S L ^a   Blythe, D ^a   English, A ^a   Richards, S J ^a   Fenton, J A L ^a   Davies, F E ^a   Child, J A ^a   Jack, A S ^a   Morgan, G J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

CD45; Differentiation; Myeloma; Proliferation; VLA 5

Indexed keywords

7 AMINODACTINOMYCIN; B LYMPHOCYTE RECEPTOR; CD103 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; GLYCOPROTEIN P 15095; INTEGRIN; KI 67 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 5;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, CD79; CELL DIFFERENTIATION; CELL DIVISION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTEGRIN ALPHA CHAINS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, FIBRONECTIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0034992767     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02730.x     Document Type: Article

References (29)

1. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma
2. Use of methyl methacrylate resin for embedding bone marrow trephine biopsy specimens
3. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells
4. Previous uptake of apoptotic neutrophgs or ligation of integrin receptors downmodulates the ability of macrophages to ingest apoptotic neutrophils
5. MPC-1-CD49e- immature myeloma cells include CD45 + subpopulations that can proliferate in response to IL-6 in human myelomas
6. Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci
7. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies
8. Phenotypic difference of normal plasma cells from mature myeloma cells
9. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis
10. Identification of immature and mature myeloma cells in the bone marrow of human myelomas
11. High proportions of VLA-5- immature myeloma cells correlated well with poor response to treatment in multiple myeloma
12. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively
13. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
14. Altered expression of Pax-5 gene in human myeloma cells
15. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis
16. CD79 Workshop Panel Report
17. Do myelomatous plasma cells really express surface immunoglobulins?
18. B cell development in the bone marrow
19. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24
20. Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells
21. Adhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumor spreading, and immortalization
22. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state
23. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage
24. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors
25. The Interleukin-6 receptor alpha chain (CD126) is expressed by neoplastic but not normal plasma cells
26. A new staging system for multiple myeloma based on the number of S-phase plasma cells
27. Fibronectin receptor structures in the VLA family of heterodimers
28. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486
29. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host